{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:53:43Z","timestamp":1770695623915,"version":"3.49.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10157-025-02785-7","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:01:43Z","timestamp":1765382503000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["mRNA-based therapies: current progress and future prospects for treating kidney disease"],"prefix":"10.1007","volume":"30","author":[{"given":"Yiyun","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-2749","authenticated-orcid":false,"given":"Hua","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"10302","key":"2785_CR1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, et al. Chronic kidney disease. Lancet. 2021;398(10302):786\u2013802.","journal-title":"Lancet"},{"issue":"10225","key":"2785_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collabor","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"10159","key":"2785_CR3","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390.","journal-title":"Lancet"},{"key":"2785_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"2785_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7(1):166.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2785_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics\u2013developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"25","key":"2785_CR7","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman RA, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326\u201334.","journal-title":"Vaccine"},{"issue":"11","key":"2785_CR8","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976\u201388.","journal-title":"J Clin Invest"},{"issue":"3","key":"2785_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ejpb.2008.09.016","volume":"71","author":"A Yamamoto","year":"2009","unstructured":"Yamamoto A, et al. Current prospects for mRNA gene delivery. Eur J Pharm Biopharm. 2009;71(3):484\u20139.","journal-title":"Eur J Pharm Biopharm"},{"issue":"Pt 1","key":"2785_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1042\/BST0340030","volume":"34","author":"SF Newbury","year":"2006","unstructured":"Newbury SF. Control of mRNA stability in eukaryotes. Biochem Soc Trans. 2006;34(Pt 1):30\u20134.","journal-title":"Biochem Soc Trans"},{"key":"2785_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.628137","volume":"9","author":"TR Damase","year":"2021","unstructured":"Damase TR, et al. The limitless future of RNA therapeutics. Front Bioeng Biotechnol. 2021;9:628137.","journal-title":"Front Bioeng Biotechnol"},{"issue":"12","key":"2785_CR12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nsmb.3499","volume":"24","author":"SA Lima","year":"2017","unstructured":"Lima SA, et al. Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017;24(12):1057\u201363.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"2785_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","volume":"19","author":"K Leppek","year":"2018","unstructured":"Leppek K, Das R, Barna M. Functional 5\u2032 UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat Rev Mol Cell Biol. 2018;19(3):158\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2785_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034728","author":"C Mayr","year":"2019","unstructured":"Mayr C. What are 3\u2032 UTRs doing? Cold Spring Harb Perspect Biol. 2019. https:\/\/doi.org\/10.1101\/cshperspect.a034728.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"16","key":"2785_CR15","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44(16):7511\u201326.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2785_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.molcel.2022.03.032","volume":"82","author":"H Bae","year":"2022","unstructured":"Bae H, Coller J. Codon optimality-mediated mRNA degradation: linking translational elongation to mRNA stability. Mol Cell. 2022;82(8):1467\u201376.","journal-title":"Mol Cell"},{"issue":"1","key":"2785_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrm.2017.91","volume":"19","author":"G Hanson","year":"2018","unstructured":"Hanson G, Coller J. Codon optimality, bias and usage in translation and mRNA decay. Nat Rev Mol Cell Biol. 2018;19(1):20\u201330.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2785_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","volume":"160","author":"V Presnyak","year":"2015","unstructured":"Presnyak V, et al. Codon optimality is a major determinant of mRNA stability. Cell. 2015;160(6):1111\u201324.","journal-title":"Cell"},{"key":"2785_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson NAC, et al. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11.","journal-title":"NPJ Vaccines"},{"issue":"3","key":"2785_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbagrm.2018.09.011","volume":"1862","author":"A Galloway","year":"2019","unstructured":"Galloway A, Cowling VH. mRNA cap regulation in mammalian cell function and fate. Biochim Biophys Acta Gene Regul Mech. 2019;1862(3):270\u20139.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"2","key":"2785_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00467-021-05352-w","volume":"38","author":"T Bondue","year":"2023","unstructured":"Bondue T, et al. The potential of RNA-based therapy for kidney diseases. Pediatr Nephrol. 2023;38(2):327\u201344.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"2785_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00244-22","volume":"42","author":"KH Lui","year":"2022","unstructured":"Lui KH, et al. 3\u2032 untranslated regions are modular entities that determine polyadenylation profiles. Mol Cell Biol. 2022;42(9):e0024422.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2785_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1653","volume":"12","author":"I Pereira-Castro","year":"2021","unstructured":"Pereira-Castro I, Moreira A. On the function and relevance of alternative 3\u2032-UTRs in gene expression regulation. Wiley Interdiscip Rev RNA. 2021;12(5):e1653.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"6292","key":"2785_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.aad9868","volume":"352","author":"AG Hinnebusch","year":"2016","unstructured":"Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5\u2032-untranslated regions of eukaryotic mRNAs. Science. 2016;352(6292):1413\u20136.","journal-title":"Science"},{"issue":"3","key":"2785_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tig.2006.01.001","volume":"22","author":"TA Hughes","year":"2006","unstructured":"Hughes TA. Regulation of gene expression by alternative untranslated regions. Trends Genet. 2006;22(3):119\u201322.","journal-title":"Trends Genet"},{"issue":"4","key":"2785_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski PS, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710\u201328.","journal-title":"Mol Ther"},{"issue":"4","key":"2785_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","volume":"136","author":"J Houseley","year":"2009","unstructured":"Houseley J, Tollervey D. The many pathways of RNA degradation. Cell. 2009;136(4):763\u201376.","journal-title":"Cell"},{"issue":"8","key":"2785_CR28","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer CD, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28(8):1619\u201329.","journal-title":"Nat Med"},{"issue":"25","key":"2785_CR29","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","volume":"387","author":"MJ Cowan","year":"2022","unstructured":"Cowan MJ, et al. Lentiviral gene therapy for Artemis-deficient SCID. N Engl J Med. 2022;387(25):2344\u201355.","journal-title":"N Engl J Med"},{"key":"2785_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","volume":"120","author":"SR Choudhury","year":"2017","unstructured":"Choudhury SR, et al. Viral vectors for therapy of neurologic diseases. Neuropharmacology. 2017;120:63\u201380.","journal-title":"Neuropharmacology"},{"key":"2785_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/genes10030189","author":"K Lundstrom","year":"2019","unstructured":"Lundstrom K. RNA viruses as tools in gene therapy and vaccine development. Genes (Basel). 2019. https:\/\/doi.org\/10.3390\/genes10030189.","journal-title":"Genes (Basel)"},{"key":"2785_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020102","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa A, et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12020102.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2785_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/1566523213666131223130024","volume":"14","author":"W Zhang","year":"2014","unstructured":"Zhang W, et al. Viral hybrid-vectors for delivery of autonomous replicons. Curr Gene Ther. 2014;14(1):10\u201323.","journal-title":"Curr Gene Ther"},{"key":"2785_CR34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jconrel.2019.10.028","volume":"316","author":"PPG Guimaraes","year":"2019","unstructured":"Guimaraes PPG, et al. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. J Control Release. 2019;316:404\u201317.","journal-title":"J Control Release"},{"key":"2785_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345\u201351.","journal-title":"J Control Release"},{"issue":"3","key":"2785_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","volume":"5","author":"ML Briuglia","year":"2015","unstructured":"Briuglia ML, et al. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res. 2015;5(3):231\u201342.","journal-title":"Drug Deliv Transl Res"},{"issue":"12","key":"2785_CR37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"issue":"11","key":"2785_CR38","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman KJ, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015;15(11):7300\u20136.","journal-title":"Nano Lett"},{"issue":"6","key":"2785_CR39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-024-00943-2","volume":"23","author":"JR Androsavich","year":"2024","unstructured":"Androsavich JR. Frameworks for transformational breakthroughs in RNA-based medicines. Nat Rev Drug Discov. 2024;23(6):421\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2785_CR40","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/acs.nanolett.8b01101","volume":"18","author":"RL Ball","year":"2018","unstructured":"Ball RL, et al. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. Nano Lett. 2018;18(6):3814\u201322.","journal-title":"Nano Lett"},{"issue":"23","key":"2785_CR41","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1021\/acs.accounts.1c00550","volume":"54","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang Y, Dong Y. Lipid nanoparticle-mRNA formulations for therapeutic applications. Acc Chem Res. 2021;54(23):4283\u201393.","journal-title":"Acc Chem Res"},{"issue":"11","key":"2785_CR42","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","volume":"15","author":"R Tenchov","year":"2021","unstructured":"Tenchov R, et al. Lipid nanoparticles\u2500from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982\u20137015.","journal-title":"ACS Nano"},{"issue":"1","key":"2785_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","volume":"20","author":"SH Kiaie","year":"2022","unstructured":"Kiaie SH, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20(1):276.","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"2785_CR44","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s41551-021-00815-9","volume":"6","author":"H Wang","year":"2022","unstructured":"Wang H, et al. Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue. Nat Biomed Eng. 2022;6(7):882\u201397.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"2785_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12951-020-00682-7","volume":"18","author":"B Ye","year":"2020","unstructured":"Ye B, et al. Neutrophils mediated multistage nanoparticle delivery for prompting tumor photothermal therapy. J Nanobiotechnol. 2020;18(1):138.","journal-title":"J Nanobiotechnol"},{"key":"2785_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12277","volume":"7","author":"N Yim","year":"2016","unstructured":"Yim N, et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun. 2016;7:12277.","journal-title":"Nat Commun"},{"issue":"5","key":"2785_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101266","volume":"297","author":"SJ Tsai","year":"2021","unstructured":"Tsai SJ, et al. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity. J Biol Chem. 2021;297(5):101266.","journal-title":"J Biol Chem"},{"key":"2785_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113992","volume":"178","author":"PM Glassman","year":"2021","unstructured":"Glassman PM, et al. Red blood cells: the metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers. Adv Drug Deliv Rev. 2021;178:113992.","journal-title":"Adv Drug Deliv Rev"},{"issue":"14","key":"2785_CR49","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1182\/blood-2013-04-495119","volume":"122","author":"O Levy","year":"2013","unstructured":"Levy O, et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood. 2013;122(14):e23-32.","journal-title":"Blood"},{"key":"2785_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020. https:\/\/doi.org\/10.1126\/science.aau6977.","journal-title":"Science"},{"issue":"4","key":"2785_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nbt.1830","volume":"29","author":"JG van den Boorn","year":"2011","unstructured":"van den Boorn JG, et al. SiRNA delivery with exosome nanoparticles. Nat Biotechnol. 2011;29(4):325\u20136.","journal-title":"Nat Biotechnol"},{"key":"2785_CR52","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.2147\/IJN.S328705","volume":"16","author":"H Wang","year":"2021","unstructured":"Wang H, et al. The advances of neutrophil-derived effective drug delivery systems: a key review of managing tumors and inflammation. Int J Nanomed. 2021;16:7663\u201381.","journal-title":"Int J Nanomed"},{"issue":"Pt A","key":"2785_CR53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","volume":"106","author":"P Vader","year":"2016","unstructured":"Vader P, et al. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):148\u201356.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"2785_CR54","doi-asserted-by":"publisher","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","volume":"16","author":"R Tenchov","year":"2022","unstructured":"Tenchov R, et al. Exosomes\u2500nature\u2019s lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano. 2022;16(11):17802\u201346.","journal-title":"ACS Nano"},{"issue":"4","key":"2785_CR55","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.kint.2016.03.041","volume":"90","author":"RM Williams","year":"2016","unstructured":"Williams RM, Jaimes EA, Heller DA. Nanomedicines for kidney diseases. Kidney Int. 2016;90(4):740\u20135.","journal-title":"Kidney Int"},{"issue":"15","key":"2785_CR56","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJMra1808786","volume":"384","author":"T Benzing","year":"2021","unstructured":"Benzing T, Salant D. Insights into glomerular filtration and albuminuria. N Engl J Med. 2021;384(15):1437\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"2785_CR57","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40291-020-00467-6","volume":"24","author":"JD Rubin","year":"2020","unstructured":"Rubin JD, Barry MA. Improving molecular therapy in the kidney. Mol Diagn Ther. 2020;24(4):375\u201396.","journal-title":"Mol Diagn Ther"},{"issue":"9","key":"2785_CR58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1152\/physiolgenomics.00052.2019","volume":"51","author":"L Davis","year":"2019","unstructured":"Davis L, Park F. Gene therapy research for kidney diseases. Physiol Genom. 2019;51(9):449\u201361.","journal-title":"Physiol Genom"},{"issue":"11\u201312","key":"2785_CR59","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/jgm.2931","volume":"18","author":"X Mao","year":"2016","unstructured":"Mao X, et al. Glomeruli or interstitium targeted by inter-renal injections supplemented by electroporation: still a useful tool in renal research. J Gene Med. 2016;18(11\u201312):343\u201352.","journal-title":"J Gene Med"},{"issue":"4","key":"2785_CR60","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/TP.0000000000000960","volume":"100","author":"X Zheng","year":"2016","unstructured":"Zheng X, et al. Attenuating ischemia-reperfusion injury in kidney transplantation by perfusing donor organs with siRNA cocktail solution. Transplantation. 2016;100(4):743\u201352.","journal-title":"Transplantation"},{"key":"2785_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020114","author":"N Oyama","year":"2020","unstructured":"Oyama N, et al. Effects of tissue pressure on transgene expression characteristics via renal local administration routes from ureter or renal artery in the rat kidney. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12020114.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2785_CR62","doi-asserted-by":"publisher","first-page":"F1217","DOI":"10.1152\/ajprenal.00070.2013","volume":"304","author":"PR Corridon","year":"2013","unstructured":"Corridon PR, et al. A method to facilitate and monitor expression of exogenous genes in the rat kidney using plasmid and viral vectors. Am J Physiol Renal Physiol. 2013;304(9):F1217\u201329.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"2785_CR63","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1681\/ASN.2020060775","volume":"32","author":"G Haddad","year":"2021","unstructured":"Haddad G, et al. Renal AAV2-mediated overexpression of long non-coding RNA H19 attenuates ischemic acute kidney injury through sponging of microRNA-30a-5p. J Am Soc Nephrol. 2021;32(2):323\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"2785_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111810","author":"N Oyama","year":"2021","unstructured":"Oyama N, et al. Efficient messenger RNA delivery to the kidney using renal pelvis injection in mice. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13111810.","journal-title":"Pharmaceutics"},{"key":"2785_CR65","doi-asserted-by":"publisher","first-page":"44904","DOI":"10.1038\/srep44904","volume":"7","author":"LE Woodard","year":"2017","unstructured":"Woodard LE, et al. Kidney-specific transposon-mediated gene transfer in vivo. Sci Rep. 2017;7:44904.","journal-title":"Sci Rep"},{"key":"2785_CR66","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1038\/srep11061","volume":"5","author":"J Espana-Agusti","year":"2015","unstructured":"Espana-Agusti J, et al. A minimally invasive, lentiviral based method for the rapid and sustained genetic manipulation of renal tubules. Sci Rep. 2015;5:11061.","journal-title":"Sci Rep"},{"issue":"9669","key":"2785_CR67","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119\u201332.","journal-title":"Lancet"},{"key":"2785_CR68","doi-asserted-by":"publisher","first-page":"g4797","DOI":"10.1136\/bmj.g4797","volume":"349","author":"E Jonasch","year":"2014","unstructured":"Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.","journal-title":"BMJ"},{"issue":"4","key":"2785_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun DA, et al. Beyond conventional immune-checkpoint inhibition\u2014novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18(4):199\u2013214.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6382","key":"2785_CR70","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, T\u00fcreci \u00d6. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355\u201360.","journal-title":"Science"},{"issue":"4","key":"2785_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2785_CR72","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/mt.2010.289","volume":"19","author":"SM Rittig","year":"2011","unstructured":"Rittig SM, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19(5):990\u20139.","journal-title":"Mol Ther"},{"issue":"5","key":"2785_CR73","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1108511","volume":"5","author":"SM Rittig","year":"2016","unstructured":"Rittig SM, et al. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncoimmunology. 2016;5(5):e1108511.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2785_CR74","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-021-01465-w","volume":"20","author":"H Xu","year":"2021","unstructured":"Xu H, et al. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma. Mol Cancer. 2021;20(1):159.","journal-title":"Mol Cancer"},{"key":"2785_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020396","author":"S Zhang","year":"2023","unstructured":"Zhang S, et al. LRP2 and DOCK8 are potential antigens for mRNA vaccine development in immunologically \u2018cold\u2019 KIRC tumours. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11020396.","journal-title":"Vaccines"},{"key":"2785_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110779","volume":"131","author":"S Kant","year":"2020","unstructured":"Kant S, Atta MG. Therapeutic advances in Fabry disease: the future awaits. Biomed Pharmacother. 2020;131:110779.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2785_CR77","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","volume":"27","author":"F DeRosa","year":"2019","unstructured":"DeRosa F, et al. Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy. Mol Ther. 2019;27(4):878\u201389.","journal-title":"Mol Ther"},{"issue":"4","key":"2785_CR78","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu X, et al. Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates. Am J Hum Genet. 2019;104(4):625\u201337.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2785_CR79","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.kint.2016.01.013","volume":"89","author":"EA Ivanova","year":"2016","unstructured":"Ivanova EA, et al. Cystinosin deficiency causes podocyte damage and loss associated with increased cell motility. Kidney Int. 2016;89(5):1037\u201348.","journal-title":"Kidney Int"},{"issue":"7","key":"2785_CR80","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.molmed.2021.04.004","volume":"27","author":"A Jamalpoor","year":"2021","unstructured":"Jamalpoor A, et al. Molecular mechanisms and treatment options of nephropathic cystinosis. Trends Mol Med. 2021;27(7):673\u201386.","journal-title":"Trends Mol Med"},{"issue":"8","key":"2785_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042840","volume":"7","author":"DM Iglesias","year":"2012","unstructured":"Iglesias DM, et al. Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulation in vitro. PLoS ONE. 2012;7(8):e42840.","journal-title":"PLoS ONE"},{"key":"2785_CR82","doi-asserted-by":"publisher","DOI":"10.1101\/2023.04.28.538106","author":"T Bondue","year":"2023","unstructured":"Bondue T, et al. CTNS mRNA as a potential treatment for nephropathic cystinosis. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.04.28.538106.","journal-title":"bioRxiv"},{"issue":"12","key":"2785_CR83","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/gim.2013.42","volume":"15","author":"PS Kruszka","year":"2013","unstructured":"Kruszka PS, et al. Renal growth in isolated methylmalonic acidemia. Genet Med. 2013;15(12):990\u20136.","journal-title":"Genet Med"},{"issue":"1","key":"2785_CR84","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13023-021-01851-z","volume":"16","author":"M Dao","year":"2021","unstructured":"Dao M, et al. Long-term renal outcome in methylmalonic acidemia in adolescents and adults. Orphanet J Rare Dis. 2021;16(1):220.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2785_CR85","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","volume":"21","author":"D An","year":"2017","unstructured":"An D, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548\u201358.","journal-title":"Cell Rep"},{"key":"2785_CR86","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","volume":"45","author":"D An","year":"2019","unstructured":"An D, et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine. 2019;45:519\u201328.","journal-title":"EBioMedicine"},{"issue":"2","key":"2785_CR87","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/ki.2015.97","volume":"88","author":"N Pallet","year":"2015","unstructured":"Pallet N, et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int. 2015;88(2):386\u201395.","journal-title":"Kidney Int"},{"issue":"3","key":"2785_CR88","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2022.11.034","volume":"164","author":"B Wang","year":"2023","unstructured":"Wang B, et al. AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review. Gastroenterology. 2023;164(3):484\u201391.","journal-title":"Gastroenterology"},{"key":"2785_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030648","author":"M Longo","year":"2022","unstructured":"Longo M, et al. Cutting-edge therapies and novel strategies for acute intermittent porphyria: step-by-step towards the solution. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10030648.","journal-title":"Biomedicines"},{"issue":"12","key":"2785_CR90","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","volume":"24","author":"L Jiang","year":"2018","unstructured":"Jiang L, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018;24(12):1899\u2013909.","journal-title":"Nat Med"},{"key":"2785_CR91","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2785_CR92","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.2337\/dc22-0926","volume":"45","author":"J Halminen","year":"2022","unstructured":"Halminen J, et al. Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes. Diabetes Care. 2022;45(10):2326\u201335.","journal-title":"Diabetes Care"},{"issue":"6","key":"2785_CR93","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.2337\/db20-0845","volume":"70","author":"R Firdessa-Fite","year":"2021","unstructured":"Firdessa-Fite R, et al. Soluble antigen arrays efficiently deliver peptides and arrest spontaneous autoimmune diabetes. Diabetes. 2021;70(6):1334\u201346.","journal-title":"Diabetes"},{"issue":"1","key":"2785_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-8587(18)30109-8","volume":"7","author":"BO Roep","year":"2019","unstructured":"Roep BO, Wheeler DCS, Peakman M. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol. 2019;7(1):65\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2785_CR95","first-page":"27","volume":"4","author":"SR Dastagir","year":"2017","unstructured":"Dastagir SR, et al. Efficient presentation of multiple endogenous epitopes to both CD4(+) and CD8(+) diabetogenic T cells for tolerance. Mol Ther. 2017;4:27\u201338.","journal-title":"Mol Ther"},{"key":"2785_CR96","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.omtm.2019.10.015","volume":"16","author":"R Firdessa-Fite","year":"2020","unstructured":"Firdessa-Fite R, Creusot RJ. Nanoparticles versus dendritic cells as vehicles to deliver mRNA encoding multiple epitopes for immunotherapy. Mol Ther Methods Clin Dev. 2020;16:50\u201362.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2785_CR97","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.addr.2017.12.019","volume":"129","author":"MV Nastase","year":"2018","unstructured":"Nastase MV, et al. Targeting renal fibrosis: mechanisms and drug delivery systems. Adv Drug Deliv Rev. 2018;129:295\u2013307.","journal-title":"Adv Drug Deliv Rev"},{"key":"2785_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100716","volume":"21","author":"C Ding","year":"2023","unstructured":"Ding C, et al. Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis. Mater Today Bio. 2023;21:100716.","journal-title":"Mater Today Bio"},{"issue":"1","key":"2785_CR99","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13287-020-01932-z","volume":"11","author":"M Lee","year":"2020","unstructured":"Lee M, et al. Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis. Stem Cell Res Ther. 2020;11(1):422.","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"2785_CR100","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess A, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015;23(9):1456\u201364.","journal-title":"Mol Ther"},{"issue":"5","key":"2785_CR101","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/mt.2012.7","volume":"20","author":"K Karik\u00f3","year":"2012","unstructured":"Karik\u00f3 K, et al. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther. 2012;20(5):948\u201353.","journal-title":"Mol Ther"},{"issue":"1","key":"2785_CR102","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","volume":"10","author":"M Maugeri","year":"2019","unstructured":"Maugeri M, et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat Commun. 2019;10(1):4333.","journal-title":"Nat Commun"},{"issue":"3","key":"2785_CR103","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"2785_CR104","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ckj\/sfab180","volume":"15","author":"C Czerlau","year":"2022","unstructured":"Czerlau C, et al. Acute interstitial nephritis after messenger RNA-based vaccination. Clin Kidney J. 2022;15(1):174\u20136.","journal-title":"Clin Kidney J"},{"issue":"2","key":"2785_CR105","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.kint.2021.05.016","volume":"100","author":"MA Anderegg","year":"2021","unstructured":"Anderegg MA, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int. 2021;100(2):474\u20136.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02785-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02785-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02785-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T11:02:37Z","timestamp":1770634957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02785-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2785"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02785-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}